Publicaciones en las que colabora con Urbano Anido Herranz (17)

2024

  1. Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer

    Frontiers in Oncology, Vol. 14

2022

  1. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

2021

  1. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group

    Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 410-415

  2. Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study

    ESMO open, Vol. 6, Núm. 2, pp. 100090

2020

  1. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus

    Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1565-1579

2019

  1. Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

    Clinical and Translational Oncology, Vol. 21, Núm. 3, pp. 249-258

2018

  1. Abordaje del paciente con cáncer renal: ¿existe la colaboración entre urología y oncología?

    Actas Urologicas Espanolas

  2. Real world data of nivolumab for previously treated non-small cell lung cancer patients: A Galician lung cancer group clinical experience

    Translational Lung Cancer Research, Vol. 7, Núm. 3, pp. 404-415

2017

  1. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, Núm. 7, pp. 1517-1522

  2. Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial

    European Journal of Cancer, Vol. 87, pp. 30-37

2016

  1. Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU)

    Current Oncology Reports, Vol. 18, Núm. 12

2014

  1. High incidence of large deletions in the PMS2 gene in Spanish Lynch syndrome families

    Clinical Genetics, Vol. 85, Núm. 6, pp. 583-588

2013

  1. Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

    Clinical and Translational Oncology, Vol. 15, Núm. 6, pp. 425-433

  2. Erratum: Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor (Clinical and Translational Oncology DOI: 10.1007/s12094-012-0985-x)

    Clinical and Translational Oncology

2010

  1. Poxviral-based prostate-specific antigen vaccine in prostate cancer

    Journal of Clinical Oncology

2009

  1. Brain metastases from prostate adenocarcinoma

    Clinical and Translational Oncology, Vol. 11, Núm. 1, pp. 63-64

2008

  1. Severe hypertension and hypokalemia as first clinical manifestations in ectopic Cushing's syndrome

    Arquivos Brasileiros de Endocrinologia e Metabologia, Vol. 52, Núm. 6, pp. 1066-1070